Drug intelligence / Profile preview

bacillus coagulans

Development stage
Phase 4
Lead developer
Eastsea Pharmaceutical
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

## Overview\nBacillus coagulans is a spore-forming, lactic acid-producing probiotic bacterium used as an oral live microbial therapeutic or probiotic ingredient. In the provided clinical and publication context, it appears as live tablets, powder, and food-based formulations and is being studied across gastrointestinal and supportive-care settings including constipation, recovery of intestinal function after surgery, oral mucositis prophylaxis after hematopoietic stem cell transplantation, Helicobacter pylori-related disease, dental caries, and respiratory illness in children with asthma. Its proposed mechanism is not a single receptor-based pharmacology but modulation of the intestinal or oral microbiome and host mucosal immune environment, including suppression of potentially harmful bacteria such as Enterobacteriaceae or mutans streptococci, promotion of short-chain-fatty-acid-associated commensals such as Lachnospiraceae in some settings, and downstream effects on inflammation and barrier or ecosystem function. The exact biological properties can be strain-specific, so findings for one strain such as SANK 70258 should not be assumed to apply identically to all Bacillus coagulans products.

Brand names
NovobioticDonlacGutguru AQProlacEnterolor
Other names
Bacillus coagulans凝结芽孢杆菌live bacillus coagulansBacillus coagulans SANK 70258
02

Targets

Shigella spp. (Shigella species)

Beyond the preview

Go deeper on bacillus coagulans.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bacillus coagulans.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call